A Point Prevalence Study to Evaluate the Prevalence of Antibodies to Selected Porcine Viruses in Patients With Cystic Fibrosis Who Are Receiving Porcine-Derived Pancreatic Enzyme Replacement Therapy: A Harmonized Protocol Across Sponsors
Phase of Trial: Phase IV
Latest Information Update: 27 Sep 2016
At a glance
- Drugs Pancrelipase (Primary)
- Indications Cystic fibrosis
- Focus Pharmacodynamics
- Sponsors AbbVie
- 19 Sep 2016 Status changed from recruiting to completed.
- 22 Dec 2014 Planned End Date changed from 1 Feb 2015 to 1 Aug 2016 as reported by ClinicalTrials.gov record.
- 22 Dec 2014 Planned primary completion date changed from 1 Feb 2015 to 1 Aug 2016 as reported by ClinicalTrials.gov record.